Suppr超能文献

层次聚类识别出一组表达隐窝样分化标志物的结肠腺癌亚组,其与微卫星稳定状态相关且预后较好。

Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis.

作者信息

Droy-Dupré Laure, Bossard Céline, Volteau Christelle, Bezieau Stéphane, Laboisse Christian L, Mosnier Jean-François

机构信息

Department of Pathology, Centre Hospitalier Universitaire, Nantes, France.

出版信息

Virchows Arch. 2015 Apr;466(4):383-91. doi: 10.1007/s00428-015-1724-9. Epub 2015 Feb 11.

Abstract

The aim of this study was to identify in the group of colonic adenocarcinomas, not otherwise specified (NOS), subgroups of oncogenetic and prognostic significance based on the expression of immunohistochemical markers of epithelial cell differentiation of the gastrointestinal tract. Hierarchical clustering analysis of 122 adenocarcinomas (NOS) identified four clusters based on how closely their profile of immunohistochemical expression of differentiation markers was related: (i) a major cluster of 83 adenocarcinomas (68%) called crypt-like carcinoma (CLA) with a immunohistochemically expressing colonic crypt differentiation markers (cytokeratin 20+, CDX2+, MUC2+ or MUC2-) and (ii) three minor clusters, characterized by the loss of colonic crypt differentiation markers and/or the acquisition of expression of markers of metaplastic foveolar gastric differentiation (MUC5AC+) and/or aberrant cytokeratin 7 expression. CLAs were invariably MSS (χ (2) test: p < 0.0001). The sole parameters associated with worse overall survival of the 122 patients with adenocarcinoma (NOS) were pT stage, pN+ stage, and advanced clinical stage. Interestingly, CLA lineage of differentiation was an independent prognostic parameter for better overall survival among the 40 patients with an adenocarcinoma (NOS) stage III. In conclusion, hierarchical clustering led to the identification of a main cluster of adenocarcinoma (NOS) with crypt-like differentiation, associated with MSS status and better prognosis. Its value as a biomarker of response to conventional chemotherapeutic agents deserves to be examined in randomized therapy trials.

摘要

本研究的目的是在未另作说明(NOS)的结肠腺癌组中,基于胃肠道上皮细胞分化免疫组化标志物的表达,确定具有肿瘤发生学和预后意义的亚组。对122例(NOS)腺癌进行层次聚类分析,根据其分化标志物免疫组化表达谱的相似程度确定了四个聚类:(i)一个由83例腺癌(68%)组成的主要聚类,称为隐窝样癌(CLA),其免疫组化表达结肠隐窝分化标志物(细胞角蛋白20+、CDX2+、MUC2+或MUC2-);(ii)三个次要聚类,其特征是结肠隐窝分化标志物缺失和/或获得化生的胃小凹分化标志物(MUC5AC+)表达和/或异常细胞角蛋白7表达。CLA均为错配修复缺陷(MSS)(χ(2)检验:p < 0.0001)。122例腺癌(NOS)患者中,与总体生存较差相关的唯一参数是pT分期、pN+分期和晚期临床分期。有趣的是,在40例III期腺癌(NOS)患者中,如果是CLA分化谱系,则是总体生存较好的独立预后参数。总之,层次聚类分析导致识别出一个具有隐窝样分化的腺癌(NOS)主要聚类,其与MSS状态和较好的预后相关。其作为传统化疗药物反应生物标志物的价值值得在随机治疗试验中进行研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验